Sixty-eight previously untreated female subjects were studied: 26 patients with cervical carcinoma, 22 with endometrial carcinoma, and 20 with benign uterine diseases. These patients, together with 25 healthy female control subjects, underwent several coagulation tests, including beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) plasma levels. Of all the parameters considered, the variations in beta-TG and PF4 were the most interesting. They were increased in patients with cervical and endometrial carcinoma. The sensitivity of the two tests reached 79% (15/19) for patients with invasive cervical carcinoma and 74% (16/22) for all patients with endometrial carcinoma. Our data demonstrate that among the investigated parameters beta-TG and PF4 are the earliest disorders of the hemostatic system and are more frequently increased in the gynecologic malignancies.
Get full access to this article
View all access options for this article.
References
1.
Al-MondhiryH.: Disseminated intravascular coagulation: Experience in a major cancer center.Thromb. Diath. Haemorrh., 34: 181–193, 1975.
2.
AmbrusJ.L., AmbrusC.M., GastparH.: Studies on platelet aggregation and platelet interaction with tumor cells. In: Platelets: A Multidisciplinary Approach.de GaetanoG., and GarattiniS. (Eds.), pp. 467–480, Raven Press, New York, 1978.
3.
BrugerolasA., EllisE.G.: Incidence of hyperfibrinogenemia in 1961 patients with cancer.J. Surg. Oncol., 5: 359–364, 1973.
4.
CarteiG., PengoV., CasaraD., DanieleO., FornasieroA., FiorentinoM.: Alterazioni coagulative nel carcinoma ovarico.Reperti clinici e significatività della cinetica del radio-fibrinogeno. Tumori, Suppl., 66, 2: 50, 1980.
5.
ColmanR.W., RobboyS.J., MinnaJ.D.: Disseminated intravascular coagulation (DIC): An approach.Am. J. Med., 52: 679–687, 1972.
6.
DawesJ., SmithR.C., PepperD.S.: The release, distribution and clearance of human beta-thromboglobulin and platelet factor 4.Thromb. Res., 12: 851–861, 1978.
7.
DonatiM.B., PoggiA.: Malignancy and hemostasis.Br. J. Haematol., 44: 173–182, 1980.
8.
EdwardsE.A.: Migrating thrombophlebitis associated with carcinoma.N. Engl. J. Med., 240: 1031–1035, 1949.
9.
FarrellR.J., DuffyM.J., DuffyG.J., MoriartyM.J.: Elevated plasma beta-thromboglobulin in patients with malignancy.Thromb. Haemost., 42: 410, 1979.
10.
GasicG.J., CatalfamoJ.L., GasicJ.B., AvdaloxicN.: In vitro mechanisms of platelet aggregation (PA) by purified plasma membrane vesicles (PMV) shed by mouse 15091 a tumor cell.Thromb. Haemost., 42: 351, 1979.
11.
GasicG.J., GasicT.B., GalantiN., JohnsonT., MurphyS.: Platelet tumor cell interaction in mice.The role of platelets in the spread of malignant disease. Int. J. Cancer, 11: 704–718, 1973.
12.
GodalH.C., AbildgaardU., KierulfP.: Ethanol gelation and fibrin monomers in plasma.Scand. J. Haematol., 13: 189–191, 1971.
13.
GralnickH.R.: Cancer cell precoagulant activity in malignancy and the hemostatic system.DonatiM.B., DavidsonJ.F., and GarattiniS. (Eds.), pp. 321–334, Raven Press, New York, 1981.
14.
HolmsenH., DayH.J., StormorkenH.: The blood platelet release reaction.Scand. J. Haematol., Suppl., 8: 1, 1969.
15.
HughesA., DauntS., VassG., WickesJ.: Beta-thromboglobulin and myocardial infarction. Seventh International Congress on Thrombosis and Haemostasis, London, 1979 (Abstract 850).
16.
JonesN.A.G., ZahaviJ., de HaasH.A., ClarkS.E., LeytonJ., KakkarV.V.: Platelet function in arterial vascular disease.Thromb. Haemost., 42: 147, 1979.
17.
LakiK.: Fibrinogen and metastasis.J. Med., 5: 32–37, 1974.
18.
LakiK., YanceyS.T.: Fibrinogen and the tumor problem. In: Fibrinogen, LakiK. (Ed.), pp. 359, Marcel Dekker, New York, 1975.
LudlanC.A., MooreS., BoltonA.E., PepperD.S., CashJ.D.: The release of a human platelet-specific protein measured by a radioimmunoassay.Thromb. Res., 6: 543–548, 1975.
21.
MatsudaT., SekiT., OgawaraM., MiuraM., YokouchiM., MurakamiM.: Comparison between plasma levels of beta-thromboglobulin and platelet factor 4 in various diseases.Thromb. Haemost., 42: 288, 1979.
22.
MautM.J., KingE.G.: Severe, acute disseminated intravascular coagulation.A rappraisal of its pathophysiology, clinical significance and therapy based on 47 patients. Am. J. Med., 67: 557–562, 1979.
23.
MillerS.P., Sanchez-AvalosJ., StefanskyT., ZuckermanL.: Coagulation disorders in cancer.I. Clinical and laboratory studies. Cancer, 20: 1452–1465, 1967.
24.
MooreS., PepperD.S., CashJ.D.: The isolation and characterization of a platelet-specific beta-globulin (beta-thromboglobulin) and detection of antiurokinase and antiplasmin released from thrombin-aggregated washed human platelets.Biochem. Biophys. Acta, 379: 360–369, 1975.
25.
MusumeciV., ZappacostaB., ElamthurnthilJ., CarloniL., MarraR.: A new automated fibrinogen assay by using a standard prothrombin time test procedure in an automated photoelectric clot timer.Thromb. Haemost., 46: 357, 1981.
26.
PearlsteinE., CooperL.B., KarpatkinS.: Extraction and characterization of a platelet-aggregating material (PAM) from SV-40 transformed mouse 3T3 fibroblasts.J. Lab. Clin. Med., 93: 332–334, 1979.
27.
PeckS.D., ReiquamC.W.: Disseminated intravascular coagulation in cancer patients: Supportive evidence.Cancer, 5: 1114–1119, 1973.
SunN.C.J., McAfeeW.M., HumG.J., WeinarJ.M.: Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients.Part I, Coagulation Studies. Am. J. Clin. Pathol., 71: 10–16, 1979.
30.
TrousseauA.: Lectures on clinical medicine delivered at the Hotel Dieu, Paris.Vol. 5, London, The New Sydenham Society, 1872: 287. Translated from edition of 1968 by Cormack J.R., London.
31.
WarrenB.A.: Platelet-tumor cell interactions: Morphological studies. In: Platelets: A Multidisciplinary Approach, de GaetanoG., and GarattiniS. (Eds.), pp. 427–446, Raven Press, New York, 1978.
32.
ZahaviJ., KakkarV.V.: Beta-thromboglobulin: Aspecific marker of in vivo platelet relase reaction.Thromb. Haemost., 45: 23–29, 1980.
